A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic.

Cancer Treat Res Commun · 2023 · PMC9801690 · PMID 36608489

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

very close to statistical significancep = 0.050actually significant

This was very close to statistical significance ( p = 0.050), so a third Kaplan-Meier analysis was undertaken to assess a four-level grouping consisting of age <65 years for ED and SD, and age ≥65 years for ED and SD.

also in 143 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.